github link
Accession IconSRP052950

Genetic and drug perturbation of components in the NFkB signaling pathway in 11-18 cells

Organism Icon Homo sapiens
Sample Icon 32 Downloadable Samples
Technology Badge IconIllumina HiSeq 2000

Submitter Supplied Information

Through the study of EGFR-mutant lung adenocarcinoma we show that NFkB signaling is rapidly engaged by EGFR oncogene inhibition to promote tumor cell persistence and therapy resistance. Unexpectedly, we found that EGFR oncogene inhibition induced an EGFR-TRAF2-RIP1-IKK complex that stimulated an NFkB-mediated transcriptional survival program. We identified a direct pharmacologic NFkB inhibitor, PBS-1086, that suppressed this adaptive survival program and increased both the magnitude and duration of initial EGFR TKI response in cellular and in vivo tumor models, including a novel patient-derived NSCLC xenograft. These findings unveil NFkB as a critical adaptive survival mechanism engaged in response to EGFR oncogene inhibition and identify PBS-1086 as a promising NFkB inhibitor to eliminate disease persistence and potentially prevent the emergence of resistance in patients. Overall design: RNAseq analysis of 11-18 (EGFR-mutant lung adenocarcinoma) cells in the context of drug treatment with erlotinib and/or genetic or pharmacological inactivation of NFkB
PubMed ID
No associated PubMed ID
Publication Title
No associated publication
Total Samples
Submitter’s Institution
No associated institution
No associated authors
Alternate Accession IDs


Show of 0 Total Samples
Accession Code
Processing Information
Additional Metadata
No rows found